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The term ocular melanoma refers to a heterogeneous group of cancers of melanocytic origin. The precursor of most cases of
conjunctival melanoma is known to ophthalmologists as primary acquired melanosis. This condition passes through well-
defined stages of tumor progression. Although tumor progression is not obligatory, as a conjunctival melanocytic lesion
acquires new biologic properties it is more likely to progress further. Although junctional nevi are seldom encountered
beyond childhood and primary acquired melanosis usually develops in middle-aged individuals, these two conditions may
be histologically indistinguishable. Most junctional nevi eventually show evidence of differentiation, whereas nearly half of
the cases of primary acquired melanosis with atypia progress to melanoma. Therefore, it is possible that aging may modulate
the capability of certain clonal proliferations to differentiate. Uveal melanocytes normally reside in mesenchyme, so that the
traditional histologic criterion for establishing the diagnosis of most melanomas – breach of an epithelial basement
membrane – does not apply. Because uveal melanomas are not easily accessible to incisional biopsy (without disruption of
vision), only two points in the spectrum of tumor progression are defined clinically: nevus and melanoma. Experimental
evidence suggests that a spectrum of atypical melanocytic proliferations separates benign nevi from melanomas capable of
generating metastases. Unlike conjunctival melanomas that spread first to regional lymph nodes, choroidal and ciliary body
melanomas preferentially spread first to the liver and are examples of organ-specific metzstases. J Invest Dermatol
100:326S–331S, 1993
Among Dr. Wallace Clark’s many contributions to the field of tumor
biology is his use of cutaneous malignant melanoma as a model for
understanding tumor progression [1]. Clark recently denned cancer as
follows [1]:
Cancer is a population of abnormal cells showing temporally unrestricted
preference (continually increasing number of cells in the population)
over their normal counterparts. Such abnormal cells invade surrounding
tissues, traverse at least one basement membrane zone, grow in the
mesenchyme at the primary site, and may metastasize to different sitesy
the fully evolved cancer is a population of abnormal cells showing
temporally unrestricted growth preference over the surrounding cells and
the ability to grow in at least three different tissue compartments: the
original compartment, the mesenchyme of the primary site, and a distant
mesenchyme.
Clark further defined tumor progression as follows [1]:
Tumor progression designates a sequence of focal changes occurring
within the proliferative lesions of a neoplastic system resulting in a series
of qualitative different lesions; lesions that may progress from benign to
increasing malignancy. Viewed as a process, tumor progression is not
obligatory. Indeed, the net directionality of lesions early in a tumor
progression system is toward regression.
The subject of ocular melanoma raises particular challenges to the tumor
biologist, not only in the sense of practical management of patients, but
also in expanding and challenging our use of melanoma as a model of
tumor progression.
OCULAR MELANOMA
Ocular melanoma presents unique challenges to both the pathologist and
the ophthalmic surgeon that may not be broadly understood by the rest of
the medical community. Before the general public awareness of acquired
immunodeficiency syndrome and Alzheimer’s disease as serious medical
health problems, the disease Americans feared the most was cancer; the
disease that was most feared after cancer was blindness (The Gallup
Organization, Inc., Public knowledge and attitudes concerning blindness
– a survey sponsored by Research to Prevent Blindness, Inc., New York,
October 1965 and April 1976, unpublished data). Therefore, both the
pathologist who renders the diagnosis of ocular cancer and the surgeon
who must manage this form of cancer cause a patient to confront two of
any individual’s greatest fears: the loss of sight and the loss of life. The
challenge for ophthalmologists is to balance the desire to preserve vision
with the overriding concern for the life of the patient. Much of the debate
that envelops the ophthalmic community concerning the diagnosis,
classification, and management of ocular melanomas can be explained
by these frequently conflicting aims. For example, if melanoma covers a
large area of the conjunctiva, it is not possible technically to excise the
entire lesion; the loss of the mucous membrane with its goblet cells
would prevent the corneal surface from being properly lubricated,
resulting not only in loss of vision, but painful loss of vision. To use yet
another example, suppose an ophthalmologist encountered a patient
with a solid pigmented choroidal lesion in an eye in which the vision was
20/20, an otherwise healthy eye. To make the case even more difficult,
now imagine that the patient had lost useable vision in the opposite eye
because of amblyopia. Is the ophthalmologist willing to render the
patient blind by treating a neoplasm that might in fact be at a stage of
tumor progression in which it is not capable of generating metastases? On
the other hand, should the tumor be treated at this stage before it has a
chance to progress to the next phase of tumor progression and acquire
the ability to spawn metastases, fully cognizant of the argument that
‘‘progression is not obligatory’’?
There is one additional confounding feature that deals with
terminology. The term ocular melanoma, used in the title of this review,
is technically misleading. Actually, there are many different biologic
forms of melanoma that affect the eye. Melanoma of the conjunctiva, like
the relatively rare melanoma of the eyelid skin, tends to spread first to the
regional lymph nodes of the eye: the parotid and submandibular lymph
nodes. Uveal melanoma, on the other hand, tends to spread almost
0022-202X/93/$06.00 Copyright & 1993 by The Society for Investigative Dermatology, Inc.
326S
Departments of Ophthalmology and Pathology, University of Iowa, Iowa City,
Iowa, USA
Reprint requests to: Dr. Robert Folberg, Departments of Ophthalmology and
Pathology, University of Iowa, Iowa City, IA, 52242-1182.
Abbreviations: DMBA, 7, 12-dimethylbenz[a]anthracene; PAM, primary
acquired melanosis
exclusively first to the liver, bypassing the regional lymph nodes (there
are no demonstrated lymphatics within the uveal tract).
Even the term uveal melanoma encompasses several different
conditions. Melanomas confined to the iris tend to have a very good
prognosis [2], whereas melanomas of the posterior uveal tract (encom-
passing the choroid and ciliary body) are usually associated with a more
ominous course. Even within the group of posterior uveal melanomas,
there are significant differences: melanomas with an anterior location
(especially those of the choroid that involve a portion of the ciliary body)
tend to be more aggressive than tumors confined strictly to the posterior
pole [3]. The misuse of the term ocular melanoma is even reflected in a
large multicenter clinical trial, the Collaborative Ocular Melanoma Study
(COMS) [4], that actually studies only melanomas of the choroid that are
not situated largely in the ciliary body, thereby excluding melanomas of
the iris, conjunctiva, and eyelid.
The etiology of each of the different forms of ocular melanoma may
also be strikingly different. Although there is some evidence that sunlight
may play a role in the pathogenesis of conjunctival melanoma [5], many
conjunctival melanomas begin in the conjunctival fornices or in the
palpebral conjunctiva, surfaces that are not at all exposed to sunlight. The
most convincing evidence for the role of sunlight in the etiology of ocular
melanoma is in the iris. A majority of iris melanomas occupy a portion of
the iris below the horizontal meridian (the upper eyelid shields the
superior half of the iris from sunlight); the tendency for this tumor to
appear in blue-eyed individuals is also supportive of the role of actinic
damage in these tumors [6]. The role of sunlight in the etiology of
posterior uveal melanomas is much more problematic. Despite reports
that exposure to sunlight is related to the development of melanoma [7],
biologists have argued that the adult crystalline lens effectively blocks
ultraviolet radiation from even reaching the choroid, and that what gets
through the lens is likely to be screened out by the retinal pigment
epithelium that overlies the choroid [8]. The exposure to sunlight would
also not explain the pathogenesis of melanomas arising in the ciliary
body, not in the direct path of light entering through the pupil.
Despite these objections to the name ‘‘ocular melanoma,’’ this term is
helpful in conceptually separating melanomas that affect portions of the
eye (with all of their attendant management problems involving the
balancing of the goals of preserving vision and life) from cutaneous
melanoma.
CONJUNCTIVAL MELANOMA AND ITS PRECURSORS
The evolution of conjunctival melanocytic lesions through nevi and a
variety of other precursors more closely resembles tumor progression as
described for cutaneous melanoma than do melanomas of the posterior
uveal tract, especially the choroid.
Clark [1] defined the following stages of tumor progression in the skin:
class 1A lesions (the common melanocytic nevus) that represent clonal
proliferations of morphologically benign cells that undergo differentia-
tion; class IB lesions that demonstrate aberrant differentiation in the
initial lesion (such as an abnormal pattern of melanocytic growth in a
common nevus); class 1C lesions (such as nevi with dysplasia); class 2
lesions (such as intraepithelial atypical melanocytic hyperplasia and the
radial growth phase of primary melanoma); class 3 lesions (primary
melanoma in the vertical growth phase); and, class 4 lesions, the
metastases themselves.
Nevi of all varieties are well described in the conjunctiva [9]. The
‘‘common’’ conjunctival melanocytic nevus also undergoes phases of
maturation and differentiation. In the practice of surgical ophthalmic
pathology, junctional nevi of the conjunctiva are rarely encountered and
are seen almost exclusively in young children. These benign intra-
epithelial lesions are probably an evanescent phase in the evolution
of conjunctival nevi. The downward migration of nevus cells into
the conjunctival substantia propria (ophthalmic pathologists speak of the
conjunctival substantia propria in a manner roughly analogous to
the dermis) is frequently accompanied by the dragging of surface
epithelium into the underlying connective tissue, giving rise to the
characteristic epithelial nests and even cystic inclusions that are
distinctive clinically. Finally, connection to the surface is lost, and the
lesion is designated as a subepithelial (analogous to an intradermal)
nevus. Neurotization and other forms of neural differentiation are
described in conjunctival nevi [10]. Other forms of nevi are described
in the conjunctiva, including blue nevi and Spitz tumors. The spectrum of
benign conjunctival melanocytic lesions was reviewed recently [9].
There are a variety of conditions that produce flat, brown pigmented
lesions in the conjunctiva of adults [11]. This pigmentation, which in its
earliest stages resembles cinnamon sprinkled on a white tablecloth, may
appear to enlarge (i.e., cover increasingly wider areas of the conjunctival
surface) and become darker; these patches of pigmentation may also
shrink or become lighter. This process of ‘‘waxing and waning’’ may
continue for many years, and the lesion may never progress to malignant
melanoma in the patient’s lifetime.
Controversy surrounds the name that ophthalmologists apply to the
condition just described. Reese [12] initially designated this lesion as
‘‘pre-cancerous melanosis’’ because he believed that the majority of
patients clinically fitting this description would eventually progress to
malignant melanoma. Reese’s conception of tumor progression did not
encompass our current understanding that ‘‘tumor progression is not
obligatory.’’ By naming the lesion pre-cancerous, Reese implied (at least
initially in his career) that it was extremely likely that a patient with this
clinical presentation would develop a conjunctival melanoma.
Reese eventually reversed his position, stating that only 17% of the
patients that he had clinically followed in fact developed malignant
melanoma [13]. Unfortunately, the use of the words ‘‘pre-cancerous’’
prompted many ophthalmologists to treat the lesion aggressively. In fact,
I and others have examined orbital exenterations (removal of the eyelids,
the eye, all the mucous membranes, and all the orbital contents) for a
condition that histologically was confined to the conjunctival epithelium.
Even radial neck dissections were performed for patients carrying the
diagnosis of ‘‘pre-cancerous melanosis.’’ On the basis of this alarming
trend, Zimmerman [14] proposed an additional name for this condition,
‘‘benign acquired melanosis,’’ with the emphasis on the word benign. He
therefore hoped to discourage the practice of radical treatment for what
in many cases turned out to be purely intraepithelial disease.
Unfortunately, what the clinician called ‘‘acquired melanosis’’ (either
‘‘pre-cancerous’’ or ‘‘benign’’) encompassed a spectrum of histologic
changes, ranging from the mere hyperpignmentation of the conjunctival
epithelium without melanocytic hyperplasia through benign and atypical
melanocytic hyperplasia. Zimmerman [14] attempted to sub-classify
‘‘benign’’ acquired melanosis into two stages, depending on the degree
of conjunctival epithelial involvement from the base to the surface.
Bernardino et al [15] thoughtfully reconsidered the entire subject of
conjunctival melanoma and its precursors. Noting the fact that the
condition of ‘‘acquired melanosis’’ clinically encompassed many years
before the detection of an invasive nodule, they looked at the histology
for similarities between acquired melanosis and lentigo maligna. They
also attempted to discover conjunctival analogs to the intraepithelial
phases of superficial spreading melanoma with its characteristic pagetoid
distribution of atypical melanocytes. They argued that any condition that
involved the contiguous eyelid skin together with the conjunctiva could
not be reasonably classified as one entity in the skin and a separate entity
in the conjunctiva. In summary, they attempted to transfer the
clinicopathologic forms of cutaneous melanoma to the conjunctiva.
Many ophthalmic pathologists, including those well versed in
contemporary dermatopathology were, however, unable to reproduce
the classification posed by Bernardino et al [5] and others [16–18]. Often,
one portion of a conjunctival biopsy would closely resemble lentigo
maligna, whereas another portion of the biopsy taken from the surface of
the same eye would display pagetoid distribution of atypical melano-
cytes. Also, acral lentiginous melanoma was found to be extremely rare
in the conjunctiva [19].
Confounding this entire clinicopathologic problem was the existence
of a variety of brown pigmentations of the conjunctiva that had
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absolutely nothing to do with the subsequent development of malignant
melanoma. For example, conjunctival melanomas are extraordinarily
uncommon in patients with deeply pigmented skin. This benign
pigmentation of the conjunctiva is known formally as ‘‘racial’’ melanosis
(the term is itself prejudicial: if the majority of ophthalmic pathologists
were themselves black, ‘‘racial’’ pigmentation would be the norm, and
we would be speaking about ‘‘racial’’ amelanosis). Systemic conditions,
such as Addison’s disease, may also impart bilateral conjunctival
pigmentation. A variety of local factors, such as the topical application
of certain medications (epinephrine and silver eye drops), can contribute
to surface pigmentation that has nothing to do with the evolution of
malignant melanoma of the conjunctiva. These forms of pigmentation of
the conjunctiva became known as ‘‘secondary acquired melanosis’’
(even though, in the case of argyrosis, the pigmentation was not even
melanin) [9].
The World Health Organization, trying to resolve the differences in
nomenclature between Reese’s ‘‘pre-cancerous’’ melanosis and Zimmer-
man’s ‘‘benign’’ acquired melanosis, suggested the term primary
acquired melanosis to distinguish the entity described clinically by
Reese from all of the ‘‘secondary’’ forms of conjunctival pigmentation.
Still, the histology of primary acquired melanosis (PAM) encompassed a
variety of different findings. A study of 41 cases of conjunctival PAM [20]
disclosed some additional information: the condition evidenced histolo-
gically by hyperpigmentation of the conjunctiva with or without benign
melanocytic hyperplasia had a negligible association with progression to
malignant melanoma. Nearly half of the lesions clinically fitting Reese’s
description of acquired melanosis that showed evidence of atypical
melanocytic hyperplasia showed progression to malignant melanoma
(PAM with atypia). Of the cases that demonstrate PAM with atypia, 75%
of patients with epithelioid cells in the epithelium and 90% of patients
whose predominant growth pattern did not show basilar hyperplasia
progressed to malignant melanoma. When atypical melanocytes were
confined to the basilar zone, there was only a 22% association with
evolution to malignant melanoma.
Additional analysis of these data suggested that patients who had
PAM without atypia tended to be younger than patients who had PAM
with atypia and that patients who displayed PAM with atypia tended to
be younger than patients who had conjunctival melanoma [20]. Such
data suggested that PAM without atypia might be a precursor to PAM
with atypia (although a direct evolution was never observed). In fact,
these observations did fit in well with our contemporary understanding of
tumor progression. The hypothesis was advanced that PAM without
atypia was a non-obligate precursor of PAM with atypia (the likelihood of
the former condition progressing to the latter was considered to be low)
and that PAM with atypia was likewise a non-obligate precursor of
malignant melanoma, but the likelihood of progressing from PAM with
atypia to melanoma was significantly higher than the likelihood of PAM
without atypia progressing to PAM with atypia. These data could not be
confirmed in human patients, but an animal model of conjunctival PAM
was later developed [21]. Following techniques used to establish animal
models of cutaneous melanoma, the repeated topical application of the
chemical carcinogen 7,12-dimethyl-benz[a]anthracene (DMBA) to the
conjunctiva produced a condition that clinically and histologically
resembled primary acquired melanosis, including the entire histologic
spectrum from PAM without atypia through PAM with atypia. Eventually,
tumors evolved that would now be classified as ‘‘an animal variant of
melanoma’’ [22].
Unfortunately, no one has yet enumerated clinical criteria that
permit ophthalmologists to distinguish PAM at low risk of progression to
melanoma from PAM with high risk of progression to melanoma on the
basis of clinical clues alone [20,23,24]. Therefore, ophthalmologists are
now advised to obtain multiple biopsies of the surface of the conjunctiva
so that various topographic areas may be evaluated for the presence
of histologic features highly associated with progression to malignant
melanoma [11]. For this reason, ophthalmologists continue to call
these lesions clinically by the term ‘‘acquired melanosis,’’ and
ophthalmic pathologists have been encouraged to also use the term
‘‘acquired melanosis,’’ histologically sub-classifying the lesion on the
basis of risk factors for progression to melanoma (PAMwithout atypia and
PAM with atypia, sub-classified by the growth pattern and cytologic
features) [11].
Unfortunately, this clinical and histologic classification has been
wrapped in a rather acrimonious debate between dermatopathologists
and ophthalmic pathologists [25–29]. Some dermatopathologists would
prefer a uniform nomenclature of melanocytic lesions [23,24,29], but the
ophthalmic pathologists argue that the best nomenclature is that which
provides useful information to the recipient of the pathology report – the
surgeon [26,28]. The ability of the ophthalmic pathologist to assign risk
factors for the progression of melanoma serves a guide for the delicate
balancing act of treatment that might sacrifice vision and more
conservative treatment that may spare vision.
Although our contemporary concept of tumor progression applies to
the conjunctiva in the intraepithelial stages of this condition, the
operational definition of tumor progression breaks down once there is
invasion into the substantia propria – once malignant melanoma has
developed. Some pathologists interpret the phrase ‘‘radial growth phase’’
as meaning only intraepithelial (intraepidermal disease) [30]. Clark’s [31]
conception of the radial growth phase, however, includes lesions that
have broken through the epithelial basement membrane and have
superficially invaded the underlying mesenchyme that completely lack
the capacity for metastases (e.g., thin level II cutaneous melanomas). The
problem in the conjunctiva is that the substantia propria is not
anatomically stratified into zones analogous to the papillary and reticular
dermis. Furthermore, although measurements of tumor thickness give a
rough indication of the likelihood of a patient succumbing to metastatic
conjunctival melanoma [5,19], the data are not nearly as satisfying in
separating patients at high risk for metastasis and patients at low risk for
metastasis. In fact, in one study, the histologic composition of the
intraepithelial component of a malignant melanoma had a stronger
statistical association with a likelihood of developing metastatic
melanoma than did the tumor thickness [19].
As in the skin, the conjunctiva shows examples of both indirect tumor
progression as well as direct tumor progression. Indirect tumor
progression in the skin is evidenced by those varieties of melanoma
showing some form of radial growth phase (e.g., lentigo maligna
melanoma, superficial spreading melanoma, and acral lentiginous
melanoma); direct tumor progression is evidenced by nodular melanoma
that lacks a clinically and histologically definable radial growth phase
distinct from the vertical growth phase [32]. In fact, there are forms of
‘‘nodular’’ melanoma in the conjunctiva, but these are exceedingly rare
[11,19].
There is one are of diagnostic overlap between conjunctival nevi and
PAM that deserves particular mention. Histologically, the rarely
encountered junctional nevus of childhood is identical in every respect
to PAM with atypia [9]. Melanomas of the conjunctiva are exceedingly
rare in childhood. Therefore, the scheme that Clark articulates (a clonal
proliferation that differentiates as the paradigm for a nevus) may apply to
melanocytic proliferations that begin in childhood, whereas the same
type of melanocytic proliferations that begin in adulthood are much less
likely to differentiate and are more likely to progress to malignant
melanoma. Although morphology is an imperfect predictor of biologic
events, the histologic similarity of the childhood junctional nevus and
PAM with atypia in adulthood raises the question of whether aging may
modulate the capability of the clonal proliferation to differentiate and
may explain why the early response of melanocytic proliferation in
childhood is differentiation into a nevus, whereas the melanocytic
proliferation in adulthood is more likely to evolve into a malignant
melanoma. Parenthetically, although conjunctival melanomas have been
described in patients with dysplastic nevi, there are no reliable histologic
markers to distinguish dysplastic nevi in the conjunctiva from other
conjunctival melanocytic lesions [9].
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UVEAL MELANOMA
The entire model of tumor progression appears to break down when
it is applied to melanomas of the ciliary body and choroid. First, returning
to Clark’s definition of cancer [1], there is no intraepithelial growth phase
and no basement membrane zone to be breached. Uveal melano-
cytes normally populate the mesenchyme, and when they begin to
proliferate, they begin an immediate interaction with the mesenchyme.
By the time a cutaneous melanoma is in the mesenchyme, we at
least assign the diagnosis of cancer (albeit a ‘‘radial growth phase’’ form
of cancer if it is situated superficially and a vertical growth phase if it
possesses histologic markers that are associated with a risk of metastases).
How do choroidal nevi evolve? There is no conceptual counterpart
to the junctional, compound, and intradermal (subepithelial) nevus. In
the uvea, is there a biologic counterpart to ‘‘radial growth phase
melanoma,’’ a tumor that shows a collection of cells with preferential
growth over the surrounding involvement but that lacks the ability to
metastasize?
The fact that ophthalmic pathologists recognize only two broad
classes of primary melanocytic lesions in the choroid and ciliary body
reflects the difficulty in conceptualizing the stages of tumor progression
in a system that begins in the mesenchyme: ophthalmic pathologists
recognize only uveal nevi and melanomas [33,34]. The existence of
uveal melanocytic hyperplasia was advanced as a clinical hypothesis
[35] but has never been demonstrated either clinically or histologically.
There is no mention in the ophthalmic pathology literature of atypical
melanocytic hyperplasia in the choroid.
None of this lack of information on the choroid reflects the
unsophistication of the ophthalmic pathologist or a lack of interest in
the field. Unlike a pigmented lesion on the skin that may be
photographed and biopsied, choroidal lesions may only be photo-
graphed. An incisional biopsy into a choroidal melanoma is not possible
without severely compromising vision (again, the conflict between
preserving vision and the desire to prevent death from cancer surfaces,
this time not in the context of managing a patient, but in the context of
investigating the biologic behavior of uveal melanocytic lesions). Fine-
needle aspiration biopsies have been performed on uveal melanomas
[36], and these are useful in distinguishing melanomas from metastases to
the uveal tract; however, the cytology of uveal melanomas as obtained
from fine-needle aspiration biopsies does not always match the cytology
evidenced on enucleated specimens [37]. Furthermore, cytomorpho-
metric measurements of nucleolar pleomorphism, so strongly associated
with prognosis in histologic sections of enucleated eyes [38], is not
effectively applied to fine-needle aspiration biopsies of choroidal
melanomas [36].
Because of the limited access to the histology of choroidal
melanocytic lesions, the study of the earliest forms of these lesions (nevi
and other putative precursors of melanoma) is limited to rare eyes
obtained at autopsy. Furthermore, for ophthalmic pathologists to make
sense of the autopsy findings, it is often helpful that pathologists have
access to clinical photographs of the lesion. Unfortunately, not every
patient examined clinically with an interesting pigmented lesion
donates an eye for study for post-mortem examination, and not every
eye examined for post-mortem information has been documented
clinically.
Even the examination of the eye in the pathology laboratory has been
the subject of controversy among ophthalmic pathologists. The conven-
tional technique for processing an eye with an intraocular neoplasm is to
obtain a complete cross section of the eye that includes the optic nerve,
the tumor, and the pupil in one plane. Although this provides an aesthetic
preparation, it does not permit the pathologist to view the tumor in the
way that the clinician saw the tumor. Furthermore, the conventional
incision that is made into the eye is from the scleral surface, without the
pathologist ever directly seeing the neoplasm. It is as if a dermatopathol-
ogist were to section through a cutaneous melanoma by turning the
excised specimen upside down and beginning all of the incisions into the
tumor from the subcutaneous fat, without ever looking at the epidermal
surface. An alternative technique for the examination of eyes removed for
malignant melanoma has been described [39]. This technique does not
produce one slide that contains all of the vital ocular structures (in fact,
the eye must be cut into a variety of different planes and each plane
carefully documented to reconstruct all of the structure of the eye), but
exquisitely accurate clinicopathologic correlations are possible using this
technique [40].
The only recourse, then, to the study of the earliest phases of tumor
progression in human primary uveal melanoma is an animal model.
Unfortunately, until recently, no animal models of primary uveal
melanoma were described in eyes large enough to document the clinical
evolution of the lesion. Most of the animal models of uveal melanoma
involve the transplantation of Greene cutaneous hamster melanoma into
the eyes of rabbits [41]. The rabbit eye is large enough to permit serial
fundus photography, but the hetero-transplant of tumor is irrelevant to the
study of in situ tumor progression (the development of a neoplasm from
the native tissue).
We recently described the induction of primary uveal melano-
cytic lesions in the choroid of rabbits following the chronic topical
application of DMBA to the rabbit sclera [42], We were able to
document photographically the emergence of flat, choroidal pigmented
lesions from the normal rabbit fundus. In a subsequent series of
experiments [43], we documented that chronic irritation of the rabbit
choroid through episcleral debridement followed by the topical chronic
application of acetone leads to a form of cytologically benign
melanocytic hyperplasia that histologically resembles what ophthalmic
pathologists call uveal nevi. Furthermore, we have now documented
various grades of cytologic atypia that may emerge within these
hyperplastic lesions after exposure to DMBA and croton oil. Some of
the lesions induced by initiation with DMBA and promotion with croton
oil consist of confluent cytologically atypical cells, at least histologically
resembling melanoma but without the biologic evidence of preferential
growth over the surrounding environment and the expansion within
space and time. These experiments have not proceeded for relatively
long periods of time, and we are not certain if continued promotion will
eventually result in an animal model of a tumor that is capable of
producing metastases.
One of the other observations to stem from these carcinogenesis
experiments is that flat, pigmented choroidal lesions may be induced
after initiation with DMBA and promotion with croton oil, but that after
withdrawal of the promotor, the fundus pigmentation disappears;
histologically, foci of cytologic atypia persist in areas of clinical
regression [43]. These experiments suggest that the dichotomous
classification of uveal melanocytic lesions into nevi and melanomas is
oversimplified: there is a sequence of such proliferations beginning with
benign uveal melanocytic hyperplasia at one end followed by the
emergence of individual foci of atypia within these hyperplastic lesions
and the development of uveal melanoma on the opposite end. In fact, if
one disregards the geometry of the uvea as lacking in epithelial basement
membrane, then these experimentally induced lesions would suggest a
type of tumor progression does in fact apply to the uveal melanocytic
system, at least in its earlier stages.
If further experimentation demonstrates that such lesions can be
promoted to melanoma (with the intriguing possibility that ultraviolet
light can be used as a promoter in a system initiated with DMBA [44,45]
in the eye, thus enabling us to test the clinical hypothesis that ultraviolet
light plays a role in the induction of human uveal melanoma), then we
will still have unraveled only a part of the story of tumor progression in
the uvea: the development of precursor lesions to the phase of
melanoma. We will still be left without an answer as to how the
melanoma itself evolves from a lesion that is histologically malignant,
through stages that define its ability to spawn metastases. Preliminary
investigations in our laboratory suggest that the induction of certain
morphologic patterns of tumor vasculature is a marker of the capability of
choroidal melanoma to generate metastases [46].
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Melanoma of the uvea offers a final challenge to the student of
melanocytic neoplasia – the riddle of organ-specific metastases.
Even were we to unravel all of the details of the evolution of primary
choroidal melanoma through its precursors, and even were we to identify
histologic markers of tumor progression that signal the capability of a
uveal melanoma to spawn metastases, we still would be left the problem
of explaining why uveal melanoma spreads almost exclusively to the
liver first. An obvious explanation would be that the uvea lacks
lymphatics, but this does not explain why the uveal melanoma bypasses
the lung and other vital organs. Considerable energy has been spent on
the experimental aspects of organ-specific metastases [47], but the one
human tumor system that begs for research attention is primary human
choroidal melanoma
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